secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0001104659-25-118292
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA says uniQure's AMT-130 Phase I/II data unlikely to support BLA submission
-----------------------------------------------------------------------------

- FDA final meeting minutes from Oct 29 pre-BLA meeting: Phase I/II data for AMT-130 unlikely to support BLA submission.
- uniQure plans to request follow-up FDA meeting in Q1 2026 to discuss path forward.
- AMT-130 targets Huntington's disease; company evaluating FDA feedback.
- CEO Matt Kapusta reaffirms commitment to advancing AMT-130.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465925118292/0001104659-25-118292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465925118292/qure-20251204x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-118292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer